Question 1

Am I eligible for this trial based on my current health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer clinical trial (NCT04523857). Contact the study team or your healthcare provider for specific answers.

Question 2

How do abemaciclib and hydroxychloroquine work together to target cancer cells?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer clinical trial (NCT04523857). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of these medications?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer clinical trial (NCT04523857). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for visits during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer clinical trial (NCT04523857). Contact the study team or your healthcare provider for specific answers.

Question 5

What will happen if I experience side effects or complications during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer clinical trial (NCT04523857). Contact the study team or your healthcare provider for specific answers.

Question 6

How does this trial compare to other treatment options available for my condition?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer clinical trial (NCT04523857). Contact the study team or your healthcare provider for specific answers.

What this study is about